Digital Therapeutics
About 2% of global population suffers from OCD, of which only about 10% are receiving treatment
OC Free™
Investigational SaMD for contamination OCD*
*Obsessive Compulsive Disorder
Among CBT*, ERP** is first-line treatment for OCD, however, only 50% experience an improvement in OCD symptoms and the dropout rate is about 25%
*Cognitive Behavioral Therapy
**Exposure and Response Prevention
OC Free™ not only improves the accessibility and effectiveness of existing OCD treatments, but enhances the QOL* of patients through digitalized ERP treatment
*Quality of Life
Stage 1....
Domestic Pilot study....
Stage 2
US Pilot study
.....Stage 3
.....US Pivotal study
BIXINK strives to be a pioneer in developing Korea's first FDA-approved digital therapeutics, and is currently pursuing pilot study in the United States
l OC Free™ l
Computerized Behavioral Therapy Device for OCD
CAUTION: Investigational Device.
Limited by Federal law to investigational use.
OC Free™
Development
Timeline
*FDA Approval Target 2025
Copyright 2021 - BIXINK │ Terms of Use │ Contact │ Privacy
6F, 561 Nonhyeon-ro, Gangnam-gu, Seoul 06125, Republic of Korea
